X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-08 | ODTX | Odyssey Therapeutics, Inc. | Dimension Capital Ii, L.P. | Dir | P - Purchase | $18.00 | +1,111,111 | 3,333,516 | +50% | +$19,999,998 | |||||
2026-05-11 | ADMA | Adma Biologics, Inc. | Grossman Jerrold B | Dir | P - Purchase | $8.01 | +12,500 | 594,091 | +2% | +$100,125 | ||||||
| D | 2026-05-11 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $7.04 | -8,346 | 63,077 | -12% | -$58,756 | |||||
2026-05-08 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $56.88 | -4,961 | 49,674 | -9% | -$282,187 | ||||||
| D | 2026-05-08 | TECH | Bio-Techne Corp | Herr Amy E. | Dir | S - Sale+OE | $48.28 | -6,636 | 2,880 | -70% | -$320,386 | |||||
| D | 2026-05-11 | ODTX | Odyssey Therapeutics, Inc. | Sr One Capital Management, LLC | 10% | S - Sale+OE | $18.00 | -1,780 | 3,794,883 | 0% | -$32,040 | |||||
| D | 2026-05-11 | ODTX | Odyssey Therapeutics, Inc. | Sr One Capital Management, LLC | 10% | P - Purchase | $18.00 | +555,555 | 3,794,883 | +17% | +$9,999,990 | |||||
| D | 2026-05-08 | ODTX | Odyssey Therapeutics, Inc. | Leiden Jeffrey M | Dir | P - Purchase | $20.00 | +5,000 | 301,842 | +2% | +$100,000 | |||||
2026-05-08 | ODTX | Odyssey Therapeutics, Inc. | Haas Jason | CFO | P - Purchase | $20.00 | +1,000 | 62,908 | +2% | +$20,000 | ||||||
| D | 2026-05-11 | ODTX | Odyssey Therapeutics, Inc. | Li Nan (Ln) | Dir | P - Purchase | $18.00 | +1,111,111 | 3,333,516 | +50% | +$19,999,998 | |||||
2026-05-11 | ODTX | Odyssey Therapeutics, Inc. | Chu Shelley | Dir | P - Purchase | $18.00 | +11,111 | 11,111 | New | +$199,998 | ||||||
2026-05-07 | ATRA | Atara Biotherapeutics, Inc. | Panacea Innovation Ltd | 10% | S - Sale | $10.10 | -313,446 | 1,318,894 | -19% | -$3,165,021 | ||||||
| M | 2026-05-07 | COAG | Hemab Therapeutics Holdings, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $24.75 | +51,258 | 7,729,773 | +1% | +$1,268,594 | |||||
2026-05-07 | ATRA | Atara Biotherapeutics, Inc. | Ecor1 Capital, LLC | 10% | P - Purchase | $9.35 | +507,407 | 1,552,000 | +49% | +$4,744,255 | ||||||
| D | 2026-05-11 | KYMR | Kymera Therapeutics, Inc. | Ridloff Elena | Dir | S - Sale+OE | $87.00 | -3,000 | 0 | -100% | -$261,000 | |||||
2026-05-07 | AURA | Aura Biosciences, Inc. | Matrix Capital Management Company, LP | 10% | S - Sale | $5.64 | -6,922,870 | 0 | -100% | -$39,044,987 | ||||||
| D | 2026-05-06 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $84.14 | -5,500 | 207,023 | -3% | -$462,784 | |||||
| D | 2026-05-07 | EXEL | Exelixis, Inc. | Beckerle Mary C | Dir | S - Sale+OE | $48.45 | -7,712 | 17,524 | -31% | -$373,646 | |||||
| D | 2026-05-07 | EXEL | Exelixis, Inc. | Freire Maria C | Dir | S - Sale+OE | $46.00 | -20,634 | 100,819 | -17% | -$949,164 | |||||
2026-05-07 | EXEL | Exelixis, Inc. | Poste George | Dir | S - Sale | $45.71 | -60,000 | 118,832 | -34% | -$2,742,600 | ||||||
| D | 2026-05-07 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $3.37 | -40,000 | 906,556 | -4% | -$134,800 | |||||
2026-05-07 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | CFO | S - Sale | $40.50 | -5,000 | 21,009 | -19% | -$202,500 | ||||||
| M | 2026-05-06 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale | $38.73 | -4,855 | 1,118 | -81% | -$188,045 | |||||
2026-05-05 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $3.52 | -30,000 | 6,199,863 | 0% | -$105,600 | ||||||
| DM | 2026-05-04 | COAG | Hemab Therapeutics Holdings, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $18.39 | +2,840,429 | 6,314,525 | +82% | +$52,222,946 | |||||
2026-05-04 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $2.34 | -264 | 506,997 | 0% | -$618 | ||||||
2026-05-04 | TECX | Tectonic Therapeutic, Inc. | Ruddy Marcella K. | Chief Medical Officer | S - Sale | $30.00 | -1,065 | 67,682 | -2% | -$31,950 | ||||||
| D | 2026-05-05 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale+OE | $14.62 | -8,000 | 166,844 | -5% | -$116,996 | |||||
2026-05-04 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $57.15 | -1,962 | 135,941 | -1% | -$112,126 | ||||||
| D | 2026-05-04 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $57.15 | -5,127 | 853,760 | -1% | -$293,002 | |||||
2026-05-04 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $57.15 | -1,116 | 122,988 | -1% | -$63,778 | ||||||
2026-05-04 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $57.15 | -2,844 | 278,964 | -1% | -$162,531 | ||||||
2026-05-04 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $57.15 | -164 | 54,635 | 0% | -$9,372 | ||||||
2026-05-04 | AMGN | Amgen Inc | Grygiel Nancy A. | SVP, CCO | S - Sale | $323.73 | -1,237 | 7,115 | -15% | -$400,451 | ||||||
2026-05-01 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $63.48 | -1,625 | 38,498 | -4% | -$103,155 | ||||||
| D | 2026-05-04 | SRZN | Surrozen, Inc./De | Li Yang | Exec. VP, Research | S - Sale+OE | $33.33 | -1,584 | 17,918 | -8% | -$52,799 | |||||
| D | 2026-05-04 | SRZN | Surrozen, Inc./De | Williams Charles O | COO | S - Sale+OE | $33.33 | -2,036 | 16,571 | -11% | -$67,866 | |||||
| D | 2026-05-04 | SRZN | Surrozen, Inc./De | Parker Craig C | CEO | S - Sale+OE | $33.33 | -4,524 | 16,553 | -21% | -$150,798 | |||||
2026-05-01 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Pres, CEO | S - Sale | $18.92 | -5,467 | 600,004 | -1% | -$103,447 | ||||||
2026-05-01 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $82.04 | -2,000 | 173,371 | -1% | -$164,080 | ||||||
| D | 2026-05-01 | MRNA | Moderna, Inc. | Hussain Abbas | Dir | S - Sale+OE | $46.63 | -5,682 | 12,066 | -32% | -$264,952 | |||||
2026-05-01 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $10.05 | -22,000 | 1,078,391 | -2% | -$221,025 | ||||||
2026-05-01 | IMVT | Immunovant, Inc. | Susman Robert Graham | Dir | S - Sale | $27.17 | -2,502 | 36,394 | -6% | -$67,979 | ||||||
2026-05-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale | $56.83 | -2,250 | 160,744 | -1% | -$127,870 | ||||||
| D | 2026-05-01 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale+OE | $6.47 | -10,781 | 121,451 | -8% | -$69,753 | |||||
| D | 2026-04-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $25.37 | -7,500 | 10,503 | -42% | -$190,299 | |||||
2026-04-28 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $14.79 | -972 | 212,895 | 0% | -$14,376 | ||||||
2026-04-28 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $14.79 | -753 | 275,857 | 0% | -$11,137 | ||||||
2026-04-28 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $14.79 | -1,490 | 418,557 | 0% | -$22,037 | ||||||
| A | 2026-04-29 | CMPX | Compass Therapeutics, Inc. | Lerner Neil | CHIEF ACCOUNTING OFFICER | P - Purchase | $1.89 | +15,000 | 397,500 | +4% | +$28,350 | |||||
| A | 2026-04-29 | CMPX | Compass Therapeutics, Inc. | Anderman Jonathan | GC | P - Purchase | $1.89 | +25,000 | 196,000 | +15% | +$47,250 | |||||
| M | 2025-09-11 | ESLA | Estrella Immunopharma, Inc. | Xu Jiandong | CFO | P - Purchase | $1.24 | +2,100 | 282,188 | +1% | +$2,594 | |||||
2026-04-29 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.11 | +5,000 | 280,766 | +2% | +$5,550 | ||||||
| D | 2026-04-27 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $14.23 | -19,037 | 377,802 | -5% | -$270,897 | |||||
2026-04-28 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $129.16 | -10,000 | 632,567 | -2% | -$1,291,608 | ||||||
| D | 2026-04-27 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale+OE | $132.41 | -3,120 | 54,400 | -5% | -$413,129 | |||||
| D | 2026-04-29 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $81.18 | -30,000 | 666,195 | -4% | -$2,435,377 | |||||
2026-04-27 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Dir | S - Sale | $61.83 | -500 | 25,222 | -2% | -$30,915 | ||||||
2026-04-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $60.76 | -2,321 | 281,808 | -1% | -$141,026 | ||||||
| D | 2026-04-24 | CGEN | Compugen Ltd | Levine Zurit | SVP, Business Development | S - Sale+OE | $3.20 | -2,000 | 29,375 | -6% | -$6,400 | |||||
| D | 2026-04-24 | CGEN | Compugen Ltd | Ophir Eran | Pres, CEO | S - Sale+OE | $3.20 | -5,000 | 11,375 | -31% | -$16,001 | |||||
| DM | 2026-04-22 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $13.96 | -57,180 | 382,132 | -13% | -$798,423 | |||||
2026-04-17 | ZIVO | Zivo Bioscience, Inc. | Strome Mark E | 10% | P - Purchase | $2.00 | +100,000 | 572,942 | +21% | +$200,000 | ||||||
2026-04-22 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $15.77 | -165,150 | 2,402,095 | -6% | -$2,604,416 | ||||||
| D | 2026-04-22 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale+OE | $89.96 | -6,000 | 674,944 | -1% | -$539,772 | |||||
| D | 2026-04-22 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $90.00 | -300 | 61,202 | 0% | -$27,000 | |||||
| D | 2026-04-22 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $3.61 | -40,000 | 906,556 | -4% | -$144,400 | |||||
2026-04-23 | IMVT | Immunovant, Inc. | Girao Tiago | CFO | S - Sale | $29.62 | -25,760 | 247,596 | -9% | -$763,011 | ||||||
2026-04-23 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $29.62 | -2,754 | 251,685 | -1% | -$81,573 | ||||||
2026-04-21 | ALLO | Allogene Therapeutics, Inc. | Yoshiyama Annie | SVP, Finance | S - Sale | $2.31 | -9,586 | 124,517 | -7% | -$22,144 | ||||||
2026-04-22 | SGMO | Sangamo Therapeutics, Inc | Davis Gregory D | Head of Research, Technology | S - Sale | $0.25 | -69,827 | 115,284 | -38% | -$17,694 | ||||||
2026-04-21 | SGMO | Sangamo Therapeutics, Inc | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | S - Sale | $0.26 | -345,942 | 332,769 | -51% | -$89,184 | ||||||
| DM | 2026-04-21 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $65.24 | -9,671 | 858,887 | -1% | -$630,957 | |||||
2026-04-22 | BNTX | Biontech Se | Poetting Sierk | COO | S - Sale | $110.56 | -50,000 | 399,387 | -11% | -$5,527,960 | ||||||
| M | 2026-04-20 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.23 | +1,000 | 275,766 | 0% | +$1,230 | |||||
2026-04-21 | RGEN | Repligen Corp | Loeillot Olivier | CEO | S - Sale | $140.00 | -3,832 | 54,246 | -7% | -$536,480 | ||||||
2026-04-21 | MGTX | Meiragtx Holdings Plc | Giroux Richard | CFO, COO | S - Sale | $10.22 | -56,000 | 1,061,682 | -5% | -$572,320 | ||||||
| M | 2026-04-17 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $16.14 | -630,374 | 2,567,245 | -20% | -$10,174,788 | |||||
| DM | 2026-04-17 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $14.60 | -69,061 | 395,146 | -15% | -$1,008,622 | |||||
2026-04-17 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $60.00 | -4,000 | 118,694 | -3% | -$240,000 | ||||||
2026-04-16 | SRRK | Scholar Rock Holding Corp | Woods Keith | COO | S - Sale | $49.57 | -10,220 | 620,055 | -2% | -$506,651 | ||||||
2026-04-16 | SRRK | Scholar Rock Holding Corp | Vaishnaw Akshay | Pres of R, D | S - Sale | $49.57 | -12,246 | 630,542 | -2% | -$607,089 | ||||||
2026-04-16 | SRRK | Scholar Rock Holding Corp | Sinha Vikas | CFO | S - Sale | $49.57 | -10,410 | 619,856 | -2% | -$516,071 | ||||||
2026-04-16 | SRRK | Scholar Rock Holding Corp | Hallal David | CEO | S - Sale | $49.57 | -30,615 | 1,844,034 | -2% | -$1,517,723 | ||||||
| D | 2026-04-17 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $7.95 | -324 | 50,268 | -1% | -$2,576 | |||||
2026-04-16 | CGTX | Cognition Therapeutics Inc | Doyle John Brendan | CFO | P - Purchase | $1.13 | +10,000 | 627,509 | +2% | +$11,300 | ||||||
2026-04-16 | CGTX | Cognition Therapeutics Inc | Ricciardi Lisa | CEO, Pres | P - Purchase | $1.10 | +9,175 | 1,754,702 | +1% | +$10,093 | ||||||
2026-04-16 | CGTX | Cognition Therapeutics Inc | Caggiano Anthony | Chief Medical Officer | P - Purchase | $1.11 | +10,000 | 874,906 | +1% | +$11,100 | ||||||
| D | 2026-04-17 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $73.01 | -15,600 | 0 | -100% | -$1,138,956 | |||||
2026-04-16 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $90.00 | -2,000 | 175,371 | -1% | -$180,000 | ||||||
| D | 2026-04-15 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $150.09 | -120,000 | 999,606 | -11% | -$18,010,488 | |||||
2026-04-16 | ALEC | Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | S - Sale | $2.65 | -1,820 | 104,645 | -2% | -$4,823 | ||||||
| DM | 2026-04-14 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $14.45 | -57,180 | 408,160 | -12% | -$826,251 | |||||
2026-04-16 | AURA | Aura Biosciences, Inc. | Kilroy Conor | See Remarks | S - Sale | $7.02 | -11,738 | 217,835 | -5% | -$82,401 | ||||||
2026-04-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $140.96 | -3,000 | 176,191 | -2% | -$422,880 | ||||||
2026-04-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale | $140.96 | -3,000 | 128,779 | -2% | -$422,880 | ||||||
2026-04-14 | KYMR | Kymera Therapeutics, Inc. | Goodman Noah | Chief Business Officer | S - Sale | $90.00 | -1,347 | 50,195 | -3% | -$121,230 | ||||||
| DM | 2026-04-14 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $90.00 | -6,551 | 61,202 | -10% | -$589,598 | |||||
| DM | 2026-04-14 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale+OE | $90.01 | -9,494 | 674,956 | -1% | -$854,539 | |||||
2026-04-14 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $55.00 | -3,000 | 122,694 | -2% | -$165,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |